← All news·2026-11-17·3 min read

Isomorphic Labs Raises $5 Billion for AI Drug Design

Alphabet's company that designs drugs with AI has closed a Series C round. It is more than twice the size of the previous one.

aisciencefunding

Alphabet’s Isomorphic Labs raises $5 billion to develop AI-generated drugs

Alphabet’s Isomorphic Labs, a biotech firm using artificial intelligence to generate novel drugs, has secured $5 billion in financing. Alphabet owns Google. It’s the third time the company has received funding from outside investors (a “Series C” round). The round was led by investment firms Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz, Thrive Capital, and Alphabet itself. It’s over twice as much as the company’s last funding round ($2.1 billion).

This funding will help power the company’s drug design engine, the IsoDDE, a collection of AI models designed to generate new molecular structures that could become part of a future drug. Some of the funds will be used to get the company’s drug candidates ready for clinical trials, where they’ll be tested on humans. Currently, all we have are preclinical data, meaning the drugs were only tested in the lab prior to any human trials. They’re being developed for cancer and immunological disorders. Basically, investors are throwing $5 billion at a process that has never yielded a drug tested in humans.

Demis Hassabis, founder and CEO of Isomorphic Labs, said the engine is generating molecules “with unprecedented precision and speed.” Of course, no outside group has verified these claims, since they’re coming directly from the company. We’ll have to wait and see how well the first drug candidate fares in clinical trials. For now, this massive investment is a sign that investors are confident in the potential of AI-designed drugs. It doesn’t show that the drugs work.

Source: www.prnewswire.com

Free course

Stop reading about AI — start building with it

The free Claude Code course: your first site, tool or game — no coding. No upsells, no cross-sells — nothing to buy here.

Start free →
EAEvgenii Arsentev

Author

Evgenii Arsentev

PhD · Founder & CEO, Dad4Kids